Zamorano José L, García-Moll Xavier, Ferrari Roberto, Greenlaw Nicola
Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Rev Esp Cardiol (Engl Ed). 2014 Jul;67(7):538-44. doi: 10.1016/j.rec.2013.10.020. Epub 2014 Mar 16.
Coronary artery disease is associated with high morbidity and mortality. The objective of the CLARIFY registry is to study the treatment of outpatients with coronary artery disease in the setting of daily clinical practice.
The CLARIFY registry is a prospective registry conducted in 41 countries that included outpatients with stable coronary artery disease attending primary care or specialist units between October 2009 and June 2010. The present study describes the baseline characteristics of the Spanish cohort compared with the western European cohorts included in the registry.
A total of 33,248 patients were included: 14,726 in western Europe and 2257 in Spain (selected by 192 cardiologists). The majority of the participants in Spain were men (81%) with a mean age of 65 years. There was a higher frequency of diabetes (34% vs 25%; P<.0001), coronary artery disease family history (19% vs 31%; P<.0001), myocardial infarction (64% vs 60%; P<.0001), and stroke (5% vs 3%; P=.0007) in the Spanish cohort than in the western European cohorts. The most common treatments in the Spanish sample were lipid-lowering drugs (96%), acetylsalicylic acid (89%), and beta-blockers (74%).
Patients in the Spanish cohort are similar to those in the western European cohorts and seem to be representative of the Spanish population with coronary artery disease. Therefore, they form a suitable basis for the study of prognostic factors at 5-year follow-up.
冠状动脉疾病与高发病率和死亡率相关。CLARIFY注册研究的目的是在日常临床实践中研究门诊冠状动脉疾病患者的治疗情况。
CLARIFY注册研究是一项在41个国家进行的前瞻性注册研究,纳入了2009年10月至2010年6月期间在基层医疗或专科单位就诊的稳定型冠状动脉疾病门诊患者。本研究描述了西班牙队列与该注册研究中纳入的西欧队列的基线特征。
共纳入33248例患者:西欧14726例,西班牙2257例(由192名心脏病专家选择)。西班牙的大多数参与者为男性(81%),平均年龄65岁。与西欧队列相比,西班牙队列中糖尿病(34%对25%;P<0.0001)、冠状动脉疾病家族史(19%对31%;P<0.0001)、心肌梗死(64%对60%;P<0.0001)和中风(5%对3%;P = 0.0007)的发生率更高。西班牙样本中最常用的治疗方法是降脂药物(96%)、乙酰水杨酸(89%)和β受体阻滞剂(74%)。
西班牙队列中的患者与西欧队列中的患者相似,似乎代表了西班牙冠状动脉疾病人群。因此,它们构成了5年随访中预后因素研究的合适基础。